-
Mashup Score: 0Bezafibrate after UDCA improves survival in PBC - 4 year(s) ago
Patients with primary biliary cholangitis who received bezafibrate after incomplete response to Ocaliva showed lower risk for death or liver transplant, according to a presenter at the Digital International Liver Congress.“Ursodeoxycholic acid [Ocaliva, Intercept] is a first-line treatment for primary biliary cholangitis. As you know, 20% to 30% of patients exhibit incomplete response to
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0Current and Emerging Treatment Options for Primary Biliary Cholangitis – Gastroenterology & Hepatology - 4 year(s) ago
G&H What is the current first-line therapy for primary biliary cholangitis, and what percentage of patients do not respond to it? AB Currently, the only first-line therapy for primary biliary cholangitis (PBC) approved by the US Food and Drug Administration (FDA) is ursodeoxycholic acid. This treatment is weight-based; current guidelines recommend starting at a dose of 13 to 15…
Categories: Gastroenterology, Latest HeadlinesTweet-
A review of current first- and second-line therapies for primary biliary cholangitis with Dr Alan Bonder: https://t.co/fMez4Ss9fB | #PBC #hepatology
-
#ILC2020: Nationwide cohort in Japan shows #bezafibrate benefits #PBC as a second-line treatment after #UDCA https://t.co/bB0pwn2IEK